INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
Therapy for ankylosing spondylitis (AS) is a challenge for a physician, primarily because of a small number of therapeutic alternatives. Interleukin-17 (IL17), a novel promising therapeutic target, has been recently disclosed. The first representative of the new group of drugs – anti-IL17A monoclon...
Sparad:
| Huvudupphov: | |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Russo |
| Utgiven: |
IMA PRESS LLC
2016-09-01
|
| Serie: | Научно-практическая ревматология |
| Ämnen: | |
| Länkar: | https://rsp.mediar-press.net/rsp/article/view/2255 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|